Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Down 38.8% in December

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the recipient of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 93,300 shares, a drop of 38.8% from the December 15th total of 152,400 shares. Approximately 2.1% of the company’s shares are sold short. Based on an average daily volume of 111,600 shares, the short-interest ratio is presently 0.8 days.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI traded up $0.01 on Wednesday, reaching $2.05. The stock had a trading volume of 32,943 shares, compared to its average volume of 55,812. Brainstorm Cell Therapeutics has a 12-month low of $1.05 and a 12-month high of $11.89. The firm has a market capitalization of $11.69 million, a price-to-earnings ratio of -0.43 and a beta of 0.29. The company has a 50-day simple moving average of $1.76 and a 200-day simple moving average of $3.21.

Analyst Ratings Changes

Separately, StockNews.com cut shares of Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 8th.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.